Protalix BioTherapeutics, Inc. (PLX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
PLX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PLX Revenue Analysis (2013–2024)
As of March 2, 2026, Protalix BioTherapeutics, Inc. (PLX) generated trailing twelve-month (TTM) revenue of $61.8 million, reflecting slight decline in growth of -0.6% year-over-year. The most recent quarter (Q3 2025) recorded $17.9 million in revenue, up 14.0% sequentially.
Looking at the longer-term picture, PLX's 5-year compound annual growth rate (CAGR) stands at -0.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $65.5 million in 2023.
Revenue diversification analysis shows PLX's business is primarily driven by Product (99%), and License and Service (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), PLX has underperformed the peer group in terms of revenue growth. Compare PLX vs AGIO →
Peer Comparison
Compare PLX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PLXCurrent | $62M | -0.6% | -0.5% | 7.3% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $53.4M | -18.5% | $29.1M | 54.5% | $3.9M | 7.3% |
| 2023 | $65.5M | +37.5% | $42.5M | 64.9% | $10.5M | 16.0% |
| 2022 | $47.6M | +24.2% | $28.0M | 58.9% | $-13,014,000 | -27.3% |
| 2021 | $38.4M | -39.0% | $22.0M | 57.4% | $-20,462,000 | -53.4% |
| 2020 | $62.9M | +15.0% | $52.0M | 82.7% | $2.7M | 4.3% |
| 2019 | $54.7M | +59.7% | $43.8M | 80.1% | $-10,717,000 | -19.6% |
| 2018 | $34.2M | +62.4% | $24.9M | 72.8% | $-19,308,000 | -56.4% |
| 2017 | $21.1M | +129.1% | $5.8M | 27.7% | $-34,517,000 | -163.8% |
| 2016 | $9.2M | +110.8% | $801K | 8.7% | $-33,163,000 | -360.5% |
| 2015 | $4.4M | -71.2% | $3.6M | 83.3% | $-23,670,000 | -542.4% |
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PLX vs AGIO
See how PLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PLX's revenue growth accelerating or slowing?
PLX revenue growth slowed to -0.6%, below the 5-year CAGR of -0.5%. TTM revenue is $62M. The deceleration marks a shift from historical growth rates.
What is PLX's long-term revenue growth rate?
Protalix BioTherapeutics, Inc.'s 5-year revenue CAGR of -0.5% reflects the variable expansion pattern. Current YoY growth of -0.6% is near this long-term average.
How is PLX's revenue distributed by segment?
PLX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.